These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 7270052)

  • 41. Urinary disturbances in striatonigral degeneration and Parkinson's disease: clinical and urodynamic aspects.
    Bonnet AM; Pichon J; Vidailhet M; Gouider-Khouja N; Robain G; Perrigot M; Agid Y
    Mov Disord; 1997 Jul; 12(4):509-13. PubMed ID: 9251068
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Abnormalities of catecholamine metabolism in Parkinson's disease (author's transl)].
    Nagatsu T
    Tanpakushitsu Kakusan Koso; 1981 Aug; 26(11):1781-8. PubMed ID: 6117927
    [No Abstract]   [Full Text] [Related]  

  • 43. Idiopathic orthostatic hypotension. Biochemical and pathologic observations in 2 cases.
    Schober R; Langston JW; Forno LS
    Eur Neurol; 1975; 13(3):177-88. PubMed ID: 1080107
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dementia in Parkinson's disease. Morphometric data.
    Duyckaerts C; Gaspar P; Costa C; Bonnet AM; Hauw JJ
    Adv Neurol; 1993; 60():447-55. PubMed ID: 8420169
    [No Abstract]   [Full Text] [Related]  

  • 45. Striato-nigral degeneration. Report of a case with an unusually short course and multiple system degenerations.
    Buonanno F; Nardelli E; Onnis L; Rizzuto N
    J Neurol Sci; 1975 Dec; 26(4):545-53. PubMed ID: 1206431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [An autopsy case of striato-nigral and olivo-ponto-cerebellar degeneration (author's transl)].
    Riku S; Hashizume Y; Yanagi T; Sobue I
    Rinsho Shinkeigaku; 1980 Jul; 20(7):534-8. PubMed ID: 7460423
    [No Abstract]   [Full Text] [Related]  

  • 47. ["Striato-nigral degeneration"].
    Jellinger K; Danielczyk W
    Acta Neuropathol; 1968 Apr; 10(3):242-57. PubMed ID: 5707331
    [No Abstract]   [Full Text] [Related]  

  • 48. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I; Serbănescu A; Tudorache B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
    [No Abstract]   [Full Text] [Related]  

  • 50. Urodynamic study in the differential diagnosis between multiple system atrophy and Parkinson's disease.
    Stocchi F; Barbato L; Carbone A; Fabbrini G; Ruggieri S; Bonamartini A; Baffigo G; Agnoli A
    Adv Neurol; 1993; 60():434-7. PubMed ID: 8420168
    [No Abstract]   [Full Text] [Related]  

  • 51. Pathogenesis of nigral cell death in Parkinson's disease.
    Przedborski S
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Striatonigral degeneration. A clinicopathological study.
    Fearnley JM; Lees AJ
    Brain; 1990 Dec; 113 ( Pt 6)():1823-42. PubMed ID: 2276046
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiple system atrophy: a review of 203 pathologically proven cases.
    Wenning GK; Tison F; Ben Shlomo Y; Daniel SE; Quinn NP
    Mov Disord; 1997 Mar; 12(2):133-47. PubMed ID: 9087971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.
    Floor E
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):709-20. PubMed ID: 10875434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
    Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
    Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
    [No Abstract]   [Full Text] [Related]  

  • 57. [Clinical features of "multiple system atrophies"--olivo-ponto-cerebellar atrophy, striato-nigral degeneration and Shy-Drager syndrome].
    Hirayama K; Kita K
    Rinsho Shinkeigaku; 1985 Oct; 25(10):1196-203. PubMed ID: 4092395
    [No Abstract]   [Full Text] [Related]  

  • 58. A brief history of parkinsonism.
    Duvoisin RC
    Neurol Clin; 1992 May; 10(2):301-16. PubMed ID: 1584174
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The clinical features of Parkinson's disease in 100 histologically proven cases.
    Hughes AJ; Daniel SE; Lees AJ
    Adv Neurol; 1993; 60():595-9. PubMed ID: 8420197
    [No Abstract]   [Full Text] [Related]  

  • 60. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Brain Res Rev; 2006 Sep; 52(2):244-56. PubMed ID: 16644019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.